Lattice Semiconductor: Q4 Disappoints, Future Growth Eyedby Mark Eisenberg 13.02.2024Lattice Semiconductor reported disappointing Q4 FY2023 results, with a decline in revenue and missed sales expectations. Despite this, the company ...
New DN-404 NFT Standard: A Trading Gamechanger?by John Darbie 13.02.2024A new token standard called DN-404 aims to improve upon the flaws of ERC-404. DN-404 allows for fractionalized NFT trading ...
Pandora’s Surge Threatened by DN404 Standardby John Darbie 13.02.2024Pandora faces competition from Ethereum token standard DN404, which aims to offer a more efficient solution. Pandora's recovery and surge ...
GOP Concerns Over FDIC Fintech Policies: Transparency Neededby Mark Eisenberg 12.02.2024Three Republican members of the House Financial Services Committee have expressed concerns about the FDIC's policies on financial technology and ...
Navigating Cryptocurrency Regulations: Legal Challengesby John Darbie 12.02.2024The rise of cryptocurrencies has presented challenges for regulators worldwide. Navigating complex and varying regulations is crucial for individuals and ...
Wall Street Soars, Setting New Records Amid Calm Marketsby Mark Eisenberg 12.02.2024Wall Street reaches new highs as S&P 500 exceeds 5000 for the first time. Market rally continues, but concerns remain ...
Intuitive Machines: Stock Surge Ahead of Lunar Questby Lilu Anderson 12.02.2024Intuitive Machines' stock soars as it prepares for a historic moon mission. A successful landing would be a major achievement ...
NRx Pharmaceuticals: $5M Boost for NRX-101 Drugby Mark Eisenberg 12.02.2024NRx Pharmaceuticals receives a $5 million milestone payment for the development of its drug candidate NRX-101, supporting its progress through ...
Bitcoin Boom: ETFs Ignite Frenzy, Experts Predict Surgeby John Darbie 12.02.2024Bitcoin's recent surge in price sparks investor interest, but caution prevails in the crypto market due to vulnerabilities and uncertainty ...
Tonix Pharma’s Potential PTSD Cure: A Game-Changer?by Mark Eisenberg 12.02.2024Tonix Pharmaceuticals receives FDA clearance for its OASIS trial, evaluating the efficacy of TNX-102 SL in treating acute stress reactions ...